M1FG
VIR icon

Mach-1 Financial Group’s Vir Biotechnology VIR Stock Holding History

Mach-1 Financial Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
+11,777
New +$112K 0.05% 128

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mach-1 Financial Group's VIR Position: Q2 2026 in Review

Mach-1 Financial Group opened a new position in Vir Biotechnology (VIR) in Q2 2026: 11,777 shares worth $120K. The stake represents 0.05% of the portfolio and ranks #128 among its holdings.

237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Mach-1 Financial Group held 11,777 shares of Vir Biotechnology worth $120K as of Q2 2026.
  • Vir Biotechnology was a new Mach-1 Financial Group position in Q2 2026.
  • Vir Biotechnology made up 0.05% of Mach-1 Financial Group's portfolio in Q2 2026, its #128 holding.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Mach-1 Financial Group's 13F filing for Q2 2026, filed 29 Jul 2026.